Your browser doesn't support javascript.
loading
Reconstructing the tumor architecture into organoids.
Luo, Zhimin; Zhou, Xingwu; Mandal, Kalpana; He, Na; Wennerberg, Wally; Qu, Moyuan; Jiang, Xing; Sun, Wujin; Khademhosseini, Ali.
Afiliação
  • Luo Z; Department of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics, University of California, Los Angeles, Los Angeles, CA 90095, USA; School of Pharmacy, Xi'an Jiaotong University, Xi'an 710061, China.
  • Zhou X; Department of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA.
  • Mandal K; Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
  • He N; School of Pharmacy, Xi'an Jiaotong University, Xi'an 710061, China.
  • Wennerberg W; Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA.
  • Qu M; Department of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Clinical Research Center for Oral Dis
  • Jiang X; Department of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics, University of California, Los Angeles, Los Angeles, CA 90095, USA; School of Nursing, Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • Sun W; Department of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA. Electronic address: wsun@terasaki.org.
  • Khademhosseini A; Department of Bioengineering, California NanoSystems Institute and Center for Minimally Invasive Therapeutics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064, USA; Department of Chemical and Biomolecular Engineer
Adv Drug Deliv Rev ; 176: 113839, 2021 09.
Article em En | MEDLINE | ID: mdl-34153370
Cancer remains a leading health burden worldwide. One of the challenges hindering cancer therapy development is the substantial discrepancies between the existing cancer models and the tumor microenvironment (TME) of human patients. Constructing tumor organoids represents an emerging approach to recapitulate the pathophysiological features of the TME in vitro. Over the past decade, various approaches have been demonstrated to engineer tumor organoids as in vitro cancer models, such as incorporating multiple cellular populations, reconstructing biophysical and chemical traits, and even recapitulating structural features. In this review, we focus on engineering approaches for building tumor organoids, including biomaterial-based, microfabrication-assisted, and synthetic biology-facilitated strategies. Furthermore, we summarize the applications of engineered tumor organoids in basic cancer research, cancer drug discovery, and personalized medicine. We also discuss the challenges and future opportunities in using tumor organoids for broader applications.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Organoides / Modelos Biológicos / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Adv Drug Deliv Rev Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Holanda
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Organoides / Modelos Biológicos / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Adv Drug Deliv Rev Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Holanda